Skip to content

PVP Labs

About
Taphalgin
Arvidal
Dalardenol
Promising developments
Contacts

This Theme Supports a Custom FrontPage

Day: April 7, 2022

07 Apr

admin Posted in main No comments

2022 Phase 3 Clinical trials of Taphalgin for patients with chronic pain have been successfully completed.

Search for:

Recent Posts

2022 Phase 3 Clinical trials of Taphalgin for patients with chronic pain have been successfully completed.
Phase 3 Clinical trials of Taphalgin have commence for patients suffering with postoperative pain.
PVP Labs Group has been established in the UAE, to develop the market for PVP products in the Middle East, India, and Africa.
PVP Labs has established Taph Corporation in the United States, with the primary goal of further developing the market for Taphalagin in America. Taphalgin is PVP’s non-narcotic pain management drug; patented in the US and Canada.
PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread

Recent Comments

Archives

April 2022
March 2022
February 2022
December 2021
November 2021
April 2020
February 2020
December 2019
September 2019
July 2019

Categories

main

Meta

Log in
Entries feed
Comments feed
WordPress.org

[email protected]

20 COLLYER QUAY, #09-01, SINGAPORE, 049319

The Meydan Hotel, Grandstand, 6-th floor, Meydan Road, Nad Al Sheba, Dubai, UAE

+971 56 460 7964

©2016-2024 PVP LABS PTE.LTD

Secondary Menu